You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New research suggests that the casirivimab-imdevimab monoclonal antibody treatment for COVID-19 ...

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience -- DUBLIN--(BUSINESS WIRE)-- Horizon ...

DEAR DR. ROACH: I have had osteoporosis for a while and recently had a bone density test that again confirmed that I have it. I am not really interested in taking an oral prescription such as Fosamax, ...